We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Chemical reactions

5 October 2016 By Robyn Mak

As smartphone growth slows, Samsung heir Jay Y. Lee is targeting a nascent market for drugs made from living cells. Selling up to $2 bln of shares in the South Korean group’s BioLogics unit will test investor appetite for a developing technology and an unfamiliar business model.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)